Hunt Investment Group

Bitwise Industries Inc. is a technology ecosystem company based in Fresno, California, founded in 2013. It focuses on enhancing the local technology landscape through education, execution, and physical space. The company operates Geekwise Academy, an accelerated training program that equips individuals of all ages, particularly those from marginalized backgrounds, with essential coding skills for the modern job market. Additionally, Bitwise Industries runs a custom software development firm, Shift3 Technologies, which pairs senior developers with entry-level programmers to create software solutions. The company also emphasizes community development by providing paid apprenticeships, helping students gain practical tech experience and connect with job opportunities, while constructing vibrant workspaces in underserved areas to foster collaboration among technologists and technology companies.

Cudoni operates a leading online marketplace for pre-owned luxury goods in the UK and Europe, focusing on convenience and exceptional service for both consumers and businesses. The company manages the entire sales process, offering services such as item collection, data-driven market valuations, professional photography, and authentication. By handling these elements, Cudoni achieves higher selling prices for its clients, typically 30-50% more than if they sold their items independently. Additionally, Cudoni provides an 'Instant Purchase' option for those who prefer immediate transactions without the hassle of consignment. By exclusively controlling its inventory, the platform ensures that buyers have access to a curated selection of high-demand products, all guaranteed for authenticity and quality, with next-day delivery available. Cudoni's approach addresses the challenges of counterfeits in the luxury market, making the buying and selling of pre-loved luxury items more accessible and efficient.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in developing tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently undergoing a Phase I/Ib clinical trial; it is a TLR8 agonist conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, which is in preclinical development and targets Nectin4, found in bladder, triple-negative breast, head and neck, and non-small cell lung cancers. The company is also developing SBT8230, aimed at treating chronic hepatitis B virus infection, and exploring other agents that utilize its proprietary technology to modulate pathways in oncology and fibrosis indications. Silverback's innovative ImmunoTAC platform enables the design of therapies that are systemically delivered but act specifically at disease sites, unlocking previously inaccessible pathways for treatment.